• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Non-Invasive Prenatal Testing (NIPT) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 Product Image

Non-Invasive Prenatal Testing (NIPT) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

  • Published: January 2014
  • Region: Global
  • 68 Pages
  • Transparency Market Research

FEATURED COMPANIES

  • Ariosa Diagnostics, Inc.
  • Berry Genomics Co., Ltd
  • BGI Health
  • LifeCodexx AG
  • Natera, Inc.
  • Sequenom, Inc.
  • MORE

'Non-Invasive Prenatal Testing (NIPT) Market (MaterniT21 PLUS, verifi, Harmony, Panorama, NIFTY, PrenaTest and BambniTest) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019'

Non-invasive prenatal testing (NIPT) is used for screening pregnant women at high risk of developing fetal chromosomal aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome (monosomy X), and also for fetal sex determination.

This report studies the current market scenario and future potential for non-invasive prenatal tests globally. The major NIPTs studied in this report are MaterniT21 PLUS, Harmony, Panorama, verifi, NIFTY, PrenaTest and BambniTest. These tests have been extensively analyzed on the basis of factors such as the technology used, testing cost, reimbursement coverage and geographical reach (availability across various countries). The market size and forecasts for each of these tests have been provided in terms of USD million for the period 2012 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (CAGR) for the market for each test READ MORE >

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Sources
1.3.1.1 Secondary Research
1.3.1.2 Primary Research
1.3.2 Models

Chapter 2 Executive Summary

Chapter 3 Global Non-Invasive Prenatal Testing Market Overview
3.1 Introduction
3.2 Major Chromosomal Aneuploidies and their Incidence Rate
3.2.1 Down Syndrome
3.2.2 Edwards Syndrome
3.2.3 Patau Syndrome
3.2.4 Turner Syndrome
3.2.5 Klinefelter Syndrome
3.2.6 Jacobs Syndrome
3.2.7 Triple X Syndrome
3.3 Technological Approach for NIPT
3.4 Market Drivers
3.4.1 High incidence rate of babies born with Down syndrome
3.4.2 Rise in average maternal age
3.4.3 Increasing demand for early and non-invasive fetal testing procedures
3.5 Market Restraints
3.5.1 Regulatory guidelines and ethical hurdles
3.5.2 Limitations of NIPT
3.5.3 Availability of other screening and testing methods
3.6 Market Opportunities
3.6.1 Capitalizing on the potential presented by the emerging markets of Asia
3.7 Porter's Five Force Analysis for the Global Non-Invasive Prenatal testing Market
3.7.1 Bargaining power of suppliers
3.7.2 Bargaining power of buyers
3.7.1 Threat of substitutes
3.7.2 Threat of new entrants
3.7.3 Competitive rivalry
3.8 Market Attractiveness Analysis: Global Non-Invasive Prenatal Testing Market, by Geography

Chapter 4 Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2012 - 2019 (USD Million)
4.1 Overview
4.1.1 Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2012 – 2019 (USD Million)
4.1.2 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2012 & 2019 (Value %)
4.2 MaterniT21 PLUS
4.2.1 Global MaterniT21 PLUS Test Market Revenue, 2012 – 2019 (USD Million)
4.3 Harmony Prenatal Test
4.3.1 Global Harmony Test Market Revenue, 2012 – 2019 (USD Million)
4.4 verifi Prenatal Test
4.4.1 Global verifi Test Market Revenue, 2012 – 2019 (USD Million)
4.5 Panorama Test
4.5.1 Global Panorama Test Market Revenue, 2012 – 2019 (USD Million)
4.6 Noninvasive Fetal Trisomy (NIFTY) Test
4.6.1 Global NIFTY Test Market Revenue, 2012 – 2019 (USD Million)
4.7 BambniTest
4.7.1 Global BambniTest Test Market Revenue, 2012 – 2019 (USD Million)
4.8 PrenaTest
4.8.1 Global PrenaTest Test Market Revenue, 2012 – 2019 (USD Million)

Chapter 5 Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2012 - 2019 (USD Million)
5.1 Overview
5.1.1 Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2012 - 2019 (USD Million)
5.1.2 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2012 & 2019 (Value %)
5.2 North America
5.2.1 North America Non-Invasive Prenatal Testing Market Revenue, 2012 - 2019 (USD Million)
5.3 Europe
5.3.1 Europe Non-Invasive Prenatal Testing Market Revenue, 2012 - 2019 (USD Million)
5.4 Asia-Pacific
5.4.1 Asia-Pacific Non-Invasive Prenatal Testing Market Revenue, 2012 - 2019 (USD Million)
5.5 Rest of the World (RoW)
5.5.1 Rest of the World (RoW) Non-Invasive Prenatal Testing Market Revenue, 2012 - 2019 (USD Million)

Chapter 6 Competitive Landscape
6.1 Market Share Analysis, by Key Players, 2012 (%)

Chapter 7 Recommendations
7.1 Focus on improving technology in order to increase the accuracy, reduce the duration of result generation and price
7.2 Focus on forming alliances with diagnostic service providers in European and Asia-Pacific countries
7.3 Mergers and acquisitions

Chapter 8 Company Profiles
8.1 Ariosa Diagnostics, Inc.
8.1.1 Company Overview
8.1.2 Product Portfolio
8.1.3 Business Strategies
8.1.4 Recent Developments
8.2 Berry Genomics Co., Ltd
8.2.1 Company Overview
8.2.2 Product Portfolio
8.2.3 Business Strategies
8.2.4 Recent Developments
8.3 BGI Health
8.3.1 Company Overview
8.3.2 Product Portfolio
8.3.3 Business Strategies
8.4 LifeCodexx AG
8.4.1 Company Overview
8.4.2 Product Portfolio
8.4.3 Business Strategies
8.4.4 Recent Developments
8.5 Natera, Inc.
8.5.1 Company Overview
8.5.2 Product Portfolio
8.5.3 Business Strategies
8.5.4 Recent Developments
8.6 Sequenom, Inc.
8.6.1 Company Overview
8.6.2 Financial Overview
8.6.3 Product Portfolio
8.6.4 Business Strategies
8.6.5 Recent Developments
8.7 Verinata Health, Inc.
8.7.1 Company Overview
8.7.2 Product Portfolio
8.7.3 Recent Developments

List of Figures

FIG. 1 Non-Invasive Prenatal Testing: Market Segmentation
FIG. 2 Global Non-Invasive Prenatal Testing Market, by Test, 2012 (USD Million)
FIG. 3 Porter's Five Force Analysis: Global Non-Invasive Prenatal Testing Market
FIG. 4 Market Attractiveness Analysis: Global Non-Invasive Prenatal Testing Market, by Geography (2012)
FIG. 5 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2012 & 2019 (Value %)
FIG. 6 Global MaterniT21 PLUS Test Market Revenue, 2012 – 2019 (USD Million)
FIG. 7 Global Harmony Test Market Revenue, 2012 – 2019 (USD Million)
FIG. 8 Global verifi Test Market Revenue, 2012 – 2019 (USD Million)
FIG. 9 Global Panorama Test Market Revenue, 2012 – 2019 (USD Million)
FIG. 10 Global NIFTY Test Market Revenue, 2012 – 2019 (USD Million)
FIG. 11 Global BambniTest Test Market Revenue, 2012 – 2019 (USD Million)
FIG. 12 Global PrenaTest Test Market Revenue, 2012 – 2019 (USD Million)
FIG. 13 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2012 & 2019 (Value %)
FIG. 14 North America Non-Invasive Prenatal Testing Market Revenue, 2012 – 2019 (USD Million)
FIG. 15 Europe Non-Invasive Prenatal Testing Market Revenue, 2012 – 2019 (USD Million)
FIG. 16 Asia-Pacific Non-Invasive Prenatal Testing Market Revenue, 2012 – 2019 (USD Million)
FIG. 17 RoW Non-Invasive Prenatal Testing Market Revenue, 2012 – 2019 (USD Million)
FIG. 18 Non-Invasive Prenatal Testing: Market Share, by Key Players, 2012 (%)
FIG. 19 Annual Revenue: Sequenom, Inc., 2010 – 2012 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Non-Invasive Prenatal Testing (NIPT) Market (2012 & 2019)
TABLE 2 Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2012 – 2019 (USD Million)
TABLE 3 Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2012 – 2019 (USD Million)

Non-invasive prenatal testing is increasingly being adopted by high risk pregnant women for the screening of common fetal chromosomal aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), Turner syndrome (monosomy X) and many others. The non-invasive nature of these tests, their accuracy and safety have been the major reasons behind their popularity among gynecologists and expecting mothers. MaterniT21 was the first NIPT launched in October 2011, by U.S. based Sequenom, Inc. and since then has been leading the market with the largest market share. Sources from Sequenom, Inc. indicate that the company accounts for more than 60% unit share of the high risk pregnancy market in the U.S. Harmony, verifi, Panorama, NIFTY, PrenaTest and BambniTest are other commercially available NIPTs for detecting chromosomal abnormalities.

The exponential growth of the NIPT market is supported by factors such as high incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT and shifting trend towards child bearing at advanced maternal age (35 years or older). As maternal age is closely associated with the increasing risk of developing a fetus with chromosomal abnormalities, rising maternal age is likely to contribute to the increasing incidence of babies born with chromosomal aneuploidies. According to Down syndrome education (DSE), in the U.S., the incidence rate for Down syndrome is 1 in every 830 child births (around 4,700 annually), while in Europe the incidence rate is 1 in every 920 babies born (around 9,000 annually), indicating a large potential consumer base for NIPT. Conventional invasive prenatal genetic tests such as amniocentesis and chorionic villus sampling (CVS) are associated with the chance of miscarriage, which is the prime reason for their replacement with new non-invasive prenatal tests. These new NIPTs are based on the analysis of cell-free DNA floating in the maternal plasma and pose no risk of miscarriage.

North America held the largest share in the global NIPT market in terms of revenue in 2012, accounting for 64.5% of the total market revenue. The fact that the major market players are U.S. based along with relatively high awareness levels in the North American region about NIPT are the key factors responsible for the region's leadership position. In Europe, the market growth largely relies on the increasing penetration of these U.S. based test developers and the expected increase in acceptance of these tests. In the Asia-Pacific market, Japan, Australia, China and India represent the high growth potential markets. The presence of a large population of women preferring late pregnancy is likely to act as one of the major growth drivers in the region. In China, the market is dominated by two local players, namely, BGI Health and Berry Genomics.

Sequenom, Inc., Verinata Health, Inc. (now a part of Illumina, Inc.), Ariosa Diagnostics, Natera, Inc., BGI Health, LifeCodexx and Berry Genomics are the key players competing in the market for non-invasive prenatal testing. These players operate by marketing their proprietary non-invasive prenatal tests by forming alliances with hospitals, clinical laboratories and physician offices.

- Ariosa Diagnostics, Inc.
- BGI Health
- Berry Genomics Co., Ltd
- LifeCodexx AG
- Natera, Inc.
- Sequenom, Inc.
- Verinata Health, Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos